Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 137 resultados

UBImmune: Identification of novel therapeutic approaches to target the immune checkpoint protein B7H3 KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN tramitó un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 Immunotherapies have revolutionized the treatment of multiple cancer types in the last decade. Nonetheless, non-small cell lung cancer and t...
2025-09-01 - 2027-08-31 | Financiado

T-RAFIC: Training network for tracking and controlling therapeutic immune cells in cancer Cancer immunotherapies have been established in a growing number of clinical indications and the pace of development is massively accelerat...
2024-07-16 - 2029-03-31 | Financiado

Dust-DN: Doctoral Network on Atmospheric Dust Atmospheric dust gives us one of the most visible and detectable aspects of transboundary transport of atmospheric constituents, impacting v...
2024-07-09 - 2028-10-31 | Financiado

EPICURE: Programming the EPIcardium to CURE broken hearts KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN tramitó un HORIZON EUROPE: ERC-2023-ADG Cardiac diseases are the leading cause of death worldwide, making human cardiac regeneration one of the most critical unmet clinical needs....
2024-07-01 - 2029-06-30 | Financiado

EPICURE: Programming the EPIcardium to CURE broken hearts KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN tramitó un HORIZON EUROPE: ERC-2023-ADG Cardiac diseases are the leading cause of death worldwide, making human cardiac regeneration one of the most critical unmet clinical needs....
2024-06-26 - 2029-06-30 | Financiado

FRESCO4NoPain: Frontier RESearch COmpetences for Neuro modulation and Oscillations in Pain KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN participó en un HORIZON EUROPE: HORIZON-MSCA-2023-DN-01 Chronic pain is a major societal and economic European burden, affects one in five adults, and its inadequate relief indicates a major unmet...
2024-06-26 - 2029-01-31 | Financiado

DCanVAX: A novel immuno-oncolytic virus-based dendritic cell therapeutic cancer vaccine KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN tramitó un HORIZON EUROPE: ERC-2023-POC Following decades of development, therapeutic cancer vaccines are beginning to gain momentum in demonstrating therapeutic effects, and they...
2024-02-01 - 2025-07-31 | Financiado

EBRAINS 2.0: EBRAINS 2.0 A Research Infrastructure to Advance Neuroscience and Brain Health KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN participó en un HORIZON EUROPE: HORIZON-INFRA-2022-SERV-B-01 EBRAINS is a collaborative European Research Infrastructure designed to advance and accelerate progress in neuroscience and brain health. Th...
2023-12-14 - 2026-12-31 | Financiado

INDUX-R: Transforming European Industrial Ecosystems through eXtended Reality enhanced with human centric AI... It is a bit ironic that when Joseph von Fraunhofer did his seminal work on optics laying the foundations of XR over two centuries ago, his w...
2023-11-14 - 2026-12-31 | Financiado

LongTx: Targeting long non-coding RNAs for novel treatment strategies in vascular diseases KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN tramitó un HORIZON EUROPE: ERC-2022-COG The perception that RNAs are passive carriers of genetic information has been overturned. Due to the diverse targeting abilities and extensi...
2023-09-01 - 2028-08-31 | Financiado

IDERHA: Integration of heterogeneous Data and Evidence towards Regulatory and HTA Acceptance KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage IDERHA will address the key obstacles to achieving appropriate access, sharing, use and reuse of lung cancer data, and thus enable enhanced...
2023-05-10 - 2028-03-31 | Financiado

TSPAN14-AD: Functional analysis of TSPAN14 as a genetic risk factor for Alzheimer’s disease KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN tramitó un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 Alzheimer’s disease (AD) is the most prevalent deadly neurodegenerative disorder for which no effective treatment exists as of today. Theref...
2023-05-01 - 2025-04-30 | Financiado

IMMUNO-TEX: Overcoming resistance to immunotherapy: Immunostimulatory tumor-derived extracellular vesicles as mu... KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN tramitó un HORIZON EUROPE: ERC-2022-STG Tumor immunotherapy with immune checkpoint inhibitors (ICI) has unprecedented therapeutic potential, but its success is limited to a minorit...
2023-05-01 - 2028-04-30 | Financiado

SHIFT: MetamorphoSis of cultural Heritage Into augmented hypermedia assets For enhanced accessibiliTy and i... SHIFT is strategically conceived to deliver a set of loosely coupled, technological tools, that offers cultural heritage institutions the ne...
2022-06-08 - 2025-09-30 | Financiado

iBack-epic: Biomechanical modelling and computational imaging to identify different causes of back pain in large... KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN tramitó un HORIZON EUROPE: ERC-2021-COG Chronic back pain is a major burden and source of disability worldwide. It is primarily attributed to different biomechanical factors, but c...
2022-05-01 - 2027-04-30 | Financiado

Cor-Edit-P: Cardiac open reading frame edition to study cardiomyopathies in pigs KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN tramitó un H2020: ERC-2020-ADG Heart failure represents a common cause of death in European societies and is frequently based on dilated cardiomyopathy (DCM) which might b...
2021-12-09 - 2026-12-31 | Financiado

PRISMAP: The European medical isotope programme Production of high purity isotopes by mass separation KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN participó en un H2020: H2020-INFRAIA-2018-2020 PRISMAP - The European medical isotope programme: Production of high purity isotopes by mass separation proposes to federate a consortium of...
2021-07-07 - 2025-04-30 | Financiado

RITA-MI 2: Rituximab in patients with acute myocardial infarction a phase 2 placebo controlled randomised clin... KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN participó en un H2020: H2020-SC1-BHC-2018-2020 RITA-MI 2 will assess the impact of a novel therapeutic strategy targeting patients’ immune response on the recovery of heart function after...
2021-01-18 - 2026-05-31 | Financiado

TUM-MED